BioMolecular Synergy

Advanced Cardio-Immunology & Functional Neuro-Gastroenterology Seminar

Curriculum Syllabus for Medical Professionals

Presenter: Professor Thomas Boyle

Course Description & Rationale

This advanced seminar provides a comprehensive, clinically rigorous exploration of the Gut-Heart-Brain Axis.

Gut-Heart-Brain Axis. It is designed specifically for physicians, cardiologists, neurologists, and advanced practice providers.

Moving beyond classical independent systems models, this session reviews contemporary translational data in cardio-immunology and neuro-gastroenterology detailing the pathways by which chronic vascular and systemic inflammation drive coronary cerebrovascular and neurodegenerative pathologies.

Seminar Timeline & Structural Breakdown

Time Block Module Topic Clinical Focus

00:00 - 00:05 Interactive Baseline Assessment Pre-test diagnostic polling of attendees on current biomarker thresholds.

00:05 - 00:25 Module 1: The Inflammatory PlaquCeC ATrAch AeIt yppheenotyping (Cleerly), coronary pericoronal fat attenuation 00:25 - 00:45 Module 2: Cerebrovascular KineticCsa &rd Nioeeumrob-oBliacr rsiterro kDey nvaiam leicfst atrial appendage thrombogenesis in AFib. 00:45 - 00:55 Module 3: The Metabolite-ImmuneM Sicigronbailainl gm Aertcahbiotelict ucarescade: Choline/Carnitine metabolism to TMA/TMAO. 00:55 - 01:00 Interactive Case Review & Q&A Translational case data evaluation, CME evaluation distribution, and Core Clinical Curricula.

Module 1: Coronary Plaque Volumetrics & Translational Anti-Inflammatory Therapeutics

Plaque Phenotyping: Leveraging Artificial Intelligence in Coronary CT Angiography (CCTA) to:

classify non-calcified, low-attenuation (soft) plaque volume vs. calcified configurations, mapping structural indices prone to high-stress rupture.

• Biomarker Tracking: Utilizing High-Sensitivity C-Reactive Protein (hs-CRP) thresholds (>3 mg/L) alongside the Fat Attenuation Index (FAI-Score™) to isolate sub-clinical. perivascular tissue inflammation before physical luminal stenosis occurs.

• Targeted Pharmacology: Reviewing data from the LoDoCo2 and COLCOT clinical trials demonstrating a 31 % relative risk reduction in major adverse cardiovascular events (MACE)

utilizing low-dose colchicine (0.5 mg daily) to disrupt microtubule polymerization in neutrophils and suppress the NLRP3 Inflammasome.

Module 2: Atrial Fibrillation Thrombogenesis & Neurovascular Security Modulation

• Cardioembolic Pathophysiology: Examining stasis-induced thrombogenesis inside the left atrial appendage (LAA) secondary to non-valvular atrial fibrillation rhythms, and the hemodynamic mechanics of embolic migratory stroke paths.

• Blood-Brain Barrier (BBB) Kinetics: Analyzing the endothelial tight-junction architecture and

pericyte/astrocyte complex that restricts 98% of small-molecule central nervous system drug delivery

• Translational Therapeutics: Evaluating the application of Focused Ultrasound (FUS)

Combined with microbubbles to transiently disrupt endothelial tight junctions, facilitating targeted delivery of monoclonal antibodies (e.g., lecanemab) to clear neurotoxic amyloid-beta plaques.

Module 3: The Microbiome-Macrophage Axis & Metabolic Signaling

• The TMAO Cascade: Investigating the microbial transformation of dietary phosphatidylcholine and L-carnitine by specific gut taxa into trimethylamine (TMA), subsequently oxidized by hepatic

flavin-containing monooxygenases (FMO3) to TMAO, a metabolite that downregulates reverse

cholesterol transport and primes macrophage foam-cell creation.

L-carnitine by specific gut taxa into trimethylamine (TMA), subsequently oxidized by hepatic

flavin-containing monooxygenases (FMO3) to TMAO, a metabolite that downregulates reverse

cholesterol transport and primes macrophage foam-cell creation.

• Short-Chain Fatty Acids (SCFAs): Outlining the regulatory role of bacterial fermentation products butyrate, acetate, propionate) acting via G-protein coupled receptors (GPR41/GPR43) to downregulate systemic nuclear factor-kappa B (NF-kB) paths and preserve endothelial function.

(butyrate, acetate, propionate) acting via G-protein coupled receptors (GPR41/GPR43) to downregulate systemic nuclear factor-kappa B (NF-kB) paths and preserve endothelial function.

The markers in the Goldilox Vascular Blend include: